Back to top
more

BioDelivery Sciences International, Inc. (BDSI)

(Delayed Data from NSDQ)

$4.84 USD

4.84
695,323

+0.08 (1.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.85 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Keytruda Gets Another FDA Nod in Endometrial Cancer

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.

Has BioDelivery Sciences International (BDSI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.

Catalyst (CPRX) Q4 Earnings Lag Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.

Incyte (INCY) Label Expansion for Ruxolitinib Cream Delayed

by Zacks Equity Research

Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.

Moderna (MRNA) Early-Stage HIV Vaccine Study Begins, Stock Up

by Zacks Equity Research

Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.

Novartis (NVS) Announces Data on Zolgensma, Acquires Coalesce

by Zacks Equity Research

Novartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.

Why is Viatris (VTRS) Stock Down 25% in the Year So Far?

by Zacks Equity Research

Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.

Intellia (NTLA) Depreciates 27% Over a Month: Here's Why

by Zacks Equity Research

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.

Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML

by Zacks Equity Research

Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.

Valneva (VALN) Completes Phase III Chikungunya Vaccine Study

by Zacks Equity Research

Valneva's (VALN) phase III study evaluating its chikungunya vaccine achieves all primary and secondary endpoints. The stock rises 9.2% following the announcement.

Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal

by Zacks Equity Research

While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.

bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes

by Zacks Equity Research

bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.

Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y

by Zacks Equity Research

Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

by Zacks Equity Research

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Has Hepion Pharmaceuticals, Inc. (HEPA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and BioDelivery Sciences International (BDSI) have performed compared to their sector so far this year.

Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -35.29% and 90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

What to Expect From Precision BioSciences (DTIL) Q4 Earnings

by Zacks Equity Research

On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.

Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More

by Zacks Equity Research

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

by Zacks Equity Research

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Why the Earnings Surprise Streak Could Continue for BioDelivery (BDSI)

by Zacks Equity Research

BioDelivery (BDSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.